Lorazepam

Ativan tablets and selected concentrate manage anxiety disorders or provide short-term relief of anxiety, including anxiety associated with depressive symptoms. Loreev XR treats adult anxiety only in patients already stable on evenly divided lorazepam tablets three times daily. Ativan injection treats status epilepticus and provides adult preanesthetic sedation/anxiety relief and reduced recall. Oral long-term benefit beyond four months is not systematically established; reassess need.

Everyday stress ordinarily does not require a benzodiazepine. This focused reference gives adult injectable labeled dosing, not a pediatric status-epilepticus protocol or continuous sedation infusion regimen. Pediatric injection safety / effectiveness is not established by this label. No lorazepam autoinjector was established in the reviewed records; midazolam products must not be substituted as lorazepam.

Selected IR labels: anxiety starts at 2–3 mg/day in two or three divided doses; usual total 2–6 mg/day, labeled range 1–10 mg/day. Anxiety-related insomnia/transient situational stress: 2–4 mg at bedtime. Older/debilitated patients: start 1–2 mg/day divided and adjust cautiously. Increase gradually. Concentrate is 2 mg/mL: use its calibrated dropper, mix with liquid or semisolid food and consume all immediately; never store the mixture.

Stop stable evenly divided three-times-daily tablets; begin the same total daily mg as XR once each morning the next day. Example: tablets 1 mg three times daily → XR 3 mg each morning. Take with/without food; swallow whole or sprinkle all onto one tablespoon applesauce, drink water and consume without chewing within two hours. Do not crush. For inadequate response needing an increase, switch back to tablets for titration, stabilize, then reconvert. UGT-inhibitor initiation also requires switching to tablets for dose reduction.

Give only where airway support, vital-sign monitoring and continued seizure care are available.

After continued therapy, taper gradually using a patient-specific plan. Withdrawal may require pausing or returning to the preceding dose, then reducing more slowly; no universal taper is supplied. Injection’s acute-dose subsection requires no routine renal adjustment, but repeated doses need caution; its warnings advise against use in renal/hepatic failure. Severe hepatic disease / encephalopathy warrants careful oral dose reduction and monitoring.

All selected oral products: benzodiazepine / ingredient hypersensitivity and acute narrow-angle glaucoma. Ativan injection additionally contraindicates sleep apnea, severe respiratory insufficiency (except the specified mechanically ventilated preanesthetic context), intra-arterial use and premature-infant use because of benzyl alcohol. Its front-label instruction prohibits neonatal use. These injection restrictions must not be converted into a universal oral contraindication list.

All four selected products carry boxed warnings for concomitant opioids, abuse / misuse / addiction and dependence / withdrawal. Reserve opioid combinations for inadequate alternatives and limit dose/duration with close observation. Injection is intended for intermittent use; more frequent use can still produce dependence and require tapering.

Sedation, dizziness, weakness and unsteadiness are common oral effects; amnesia, confusion, paradoxical behavior, respiratory depression and rare hematologic/hepatic reactions are reported. Injection also causes local reactions and dose-related prolonged sedation. Overdose can cause coma/apnea, especially with other depressants: emergency airway/supportive care and Poison Help (U.S. 1-800-222-1222). Flumazenil can trigger seizures/withdrawal and is contraindicated when benzodiazepines controlled a life-threatening condition such as status epilepticus.

Observational benzodiazepine data do not show a clear major-malformation association, but cannot establish absence of risk. Late exposure may cause neonatal respiratory depression, hypotonia, feeding difficulty or withdrawal. Parenteral obstetric use is not recommended because safety data are insufficient. Lorazepam enters milk: IR/injection labels balance maternal need and monitor infant sedation, feeding and weight; Loreev XR specifically advises against breastfeeding.

IR tablet/concentrate safety below 12 is not established; XR pediatric safety / effectiveness is not established. Injection pediatric status-epilepticus efficacy/safety is not established, and preanesthetic use below 18 is not recommended. Neonatal/premature infant excipient restrictions apply. Older adults are more prone to sedation, falls and breathing impairment; oral IR starts 1–2 mg/day divided, XR requires prior stabilization, and IV preanesthetic limits for >50 remain relevant.

Glucuronide is eliminated renally and accumulates with renal dysfunction; poor dialysis of parent drug does not imply safety. Oral labels call for caution and careful response-based reduction in severe hepatic insufficiency / encephalopathy. XR has no formal renal/hepatic PK studies. Injection warnings advise against renal/hepatic failure; acute renal-dose adjustment is not required by its dosing subsection, while repeated doses and excipient exposure require caution.

Acts at the GABA-A benzodiazepine receptor complex, enhancing inhibitory signaling with anxiolytic, sedative and anticonvulsant effects.

IR oral

Bioavailability ~90%; plasma peak ~2 hours; parent half-life ~12 hours.

XR

Single fasted 3 mg median peak ~14 hours; half-life ~20 hours in studied adults; steady state ~5 days.

Injection

IM peak within ~3 hours; parenteral terminal half-life ~14 hours in studied subjects.

Metabolism / elimination

Conjugated to inactive glucuronide, mainly eliminated in urine. These population averages do not predict an individual recovery or driving time.

Assess anxiety benefit, duration/need, misuse risk, mental status, suicidality, falls and sedative co-therapy. Long-term oral labels recommend periodic blood counts and liver tests. Injection requires airway/breathing, blood pressure, seizure response and recovery monitoring; repeated/excessive doses or renal dysfunction warrant evaluation for excipient toxicity.

Never share; store securely and dispose safely. Avoid alcohol and unsafe driving/machinery while impaired; after injection avoid hazardous activities for at least 24–48 hours or until effects subside, whichever is longer. Do not stop regular therapy suddenly. Slow/shallow breathing, inability to wake, severe confusion or seizures require emergency help. Follow XR sprinkle and concentrate measuring directions exactly.

Ativan oral tablets are the representative product. Tablet appearance varies across manufacturers; packaging/pharmacy verification is necessary. Schedule IV status applies to selected products. This is not an exhaustive inventory of repackagers, generics or non-U.S. presentations.

Ativan tablets: 25°C, excursions 15–30°C, tightly closed. XR: 20–25°C, excursions 15–30°C, tightly closed. Selected concentrate: refrigerate 2–8°C, protect from light, keep tightly closed in supplied bottle and discard 90 days after opening. Ativan injection: refrigerate and protect from light in carton. Do not extrapolate one manufacturer’s beyond-use/storage directions to another product.